

Apharm Limited

Annual Report and Unaudited Financial Statements
for the Year Ended 31 July 2018

Kajaine Limited
Kajaine House
57-67 High Street
Edgware
HA8 7DD

Apharm Limited

Contents

Company Information	<u>1</u>
Balance Sheet	<u>2</u>
Notes to the Financial Statements	<u>3 to 7</u>

Apharm Limited

Company Information

Directors Mr S A Chiari
Mrs H E Chiari
Ms C H Carrigan

Registered office 175 Station Road
West Moors
Ferndown
BH22 0HX

Accountants Kajaine Limited
Kajaine House
57-67 High Street
Edgware
HA8 7DD

Apharm Limited

(Registration number: 03705212)

Balance Sheet as at 31 July 2018

	Note	2018 £	2017 £
Fixed assets			
Intangible assets	<u>4</u>	28,125	50,625
Tangible assets	<u>5</u>	51,894	53,171
		<u>80,019</u>	<u>103,796</u>
Current assets			
Stocks	<u>6</u>	65,937	61,282
Debtors	<u>7</u>	282,509	262,250
Cash at bank and in hand		300,926	379,087
		<u>649,372</u>	<u>702,619</u>
Creditors: Amounts falling due within one year	<u>8</u>	<u>(234,521)</u>	<u>(257,048)</u>
Net current assets		<u>414,851</u>	<u>445,571</u>
Net assets		<u>494,870</u>	<u>549,367</u>
Capital and reserves			
Called up share capital	<u>9</u>	5,000	5,000
Profit and loss account		<u>489,870</u>	<u>544,367</u>
Total equity		<u>494,870</u>	<u>549,367</u>

For the financial year ending 31 July 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the Board on 17 April 2019 and signed on its behalf by:

.....
Mr S A Chiari
Director

.....
Mrs H E Chiari
Director

.....
Ms C H Carrigan
Director

The notes on pages 3 to 7 form an integral part of these financial statements.

Apharm Limited

Notes to the Financial Statements for the Year Ended 31 July 2018

1 General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:

175 Station Road
West Moors
Ferndown
BH22 0HX
United Kingdom

These financial statements were authorised for issue by the Board on 17 April 2019.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:

The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Apharm Limited

Notes to the Financial Statements for the Year Ended 31 July 2018

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Fixtures, fittings and equipment	20% Reducing balance basis
Motor vehicles	25% Reducing balance basis
Leasehold property	Over the period of the lease of 80 years

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company's interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class	Amortisation method and rate
Goodwill	Over 20 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Apharm Limited

Notes to the Financial Statements for the Year Ended 31 July 2018

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Dividends

Dividend distribution to the company's shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 Staff numbers

The average monthly number of persons employed by the company (including directors) during the year, was 17 (2017 - 18).

4 Intangible assets

	Goodwill £	Total £
Cost or valuation		
At 1 August 2017	450,000	450,000
At 31 July 2018	450,000	450,000
Amortisation		
At 1 August 2017	399,375	399,375
Amortisation charge	22,500	22,500
At 31 July 2018	421,875	421,875
Carrying amount		
At 31 July 2018	28,125	28,125
At 31 July 2017	50,625	50,625

Apharm Limited

Notes to the Financial Statements for the Year Ended 31 July 2018

5 Tangible assets

	Land and buildings £	Fixtures, fittings and equipment £	Motor vehicles £	Total £
Cost or valuation				
At 1 August 2017	60,075	49,829	10,021	119,925
Additions	-	763	-	763
At 31 July 2018	60,075	50,592	10,021	120,688
Depreciation				
At 1 August 2017	12,000	47,111	7,643	66,754
Charge for the year	750	696	594	2,040
At 31 July 2018	12,750	47,807	8,237	68,794
Carrying amount				
At 31 July 2018	47,325	2,785	1,784	51,894
At 31 July 2017	48,075	2,718	2,378	53,171

Included within the net book value of land and buildings above is £47,325 (2017 - £48,075) in respect of long leasehold land and buildings.

6 Stocks

	2018 £	2017 £
Other inventories	65,937	61,282

7 Debtors

	2018 £	2017 £
Trade debtors	250,558	229,284
Other debtors	29,454	30,279
Prepayments	2,497	2,687
Total current trade and other debtors	282,509	262,250

Apharm Limited

Notes to the Financial Statements for the Year Ended 31 July 2018

8 Creditors

Creditors: amounts falling due within one year

	2018 £	2017 £
Due within one year		
Trade creditors	183,220	198,628
Taxation and social security	3,462	2,705
Other creditors	1,753	562
Accrued expenses	3,682	3,725
Corporation tax payable	4,523	14,692
Directors current account	37,881	36,736
	<u>234,521</u>	<u>257,048</u>

9 Share capital

Allotted, called up and fully paid shares

	2018		2017	
	No.	£	No.	£
Ordinary Shares of £1 each	5,000	5,000	5,000	5,000
	<u>5,000</u>	<u>5,000</u>	<u>5,000</u>	<u>5,000</u>

10 Dividends

	2018 £	2017 £
Interim dividend of £10.00 (2017 - £10.00) per ordinary share	<u>50,000</u>	<u>50,000</u>

11 Related party transactions

Directors' remuneration

The directors' remuneration for the year was as follows:

	2018 £	2017 £
Remuneration	52,558	61,408
Contributions paid to money purchase schemes	<u>12,880</u>	<u>10,416</u>
	<u>65,438</u>	<u>71,824</u>

